Compugen Ltd. to Review Second Quarter 2008 Results on Tuesday, July 29, 2008

  
    
  
  
    
      Compugen Ltd. (NASDAQ:CGEN) today announced that the Company plans to 
      host a live conference call and webcast at 10:00 AM EDT on Tuesday, July 
      29, 2008 to review second quarter 2008 results. The quarterly results 
      will be released prior to the conference call.
    
    
      During the call, management will also provide additional information 
      regarding Compugen’s recently announced drug 
      candidate for breast cancer therapy.
    
    
      To access the conference call, please dial 1-866-345-5855 from the US or 
      [phone] internationally. The call will also be available via 
      live webcast through Compugen’s Website, 
      located at www.cgen.com.
    
    
      A replay of the conference call will be available approximately two 
      hours after the completion of the live conference call. To access the 
      replay, please dial 1-888-326-9310 from the US or [phone]. 
      The replay will be available until 12 noon EDT on August 1, 2008.
    
    
      About Compugen
    
    
      Compugen’s mission is to be the world leader 
      in the discovery and licensing of product candidates to the drug and 
      diagnostic industries under milestone and revenue sharing agreements. 
      The Company’s increasing inventory of powerful 
      and proprietary discovery platforms is enabling the predictive discovery – 
      field after field – of numerous therapeutic 
      and diagnostic product candidates. These discovery platforms are based 
      on the Company’s decade-long focus on the 
      predictive understanding of important biological phenomena at the 
      molecular level. Compugen’s current 
      collaborations include Biosite, Medarex, Inc., Merck & Co., Inc., 
      Ortho-Clinical Diagnostics (a Johnson & Johnson company), Roche, Siemens 
      Healthcare Diagnostics, Inc., and Teva Pharmaceutical Industries. In 
      2002, Compugen established an affiliate, Evogene Ltd. (TASE: EVGN.TA), 
      to utilize the Company’s in-silico 
      predictive discovery capabilities in the agricultural biotechnology 
      field. For additional information, please visit Compugen's corporate 
      Website at www.cgen.com and Evogene’s 
      corporate Website at www.evogene.com.